COMMUNIQUÉS West-GlobeNewswire

Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018
20/02/2019
Strong cash reserves as Company prepares for potential US launch of remestemcel-L MELBOURNE, Australia and NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its [...]
Hoth Therapeutics Inc. Announces Closing of Initial Public Offering
20/02/2019
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as [...]
Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine
20/02/2019
Publication Highlights Safety and Efficacy Profile of Sacituzumab Govitecan Addressing High Unmet Need in Metastatic Triple-Negative Breast Cancer MORRIS PLAINS, N.J., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc [...]
MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
20/02/2019
WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, [...]
PLx Pharma Inc. Announces Completion of $15 Million Convertible Preferred Stock Financing
20/02/2019
HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“ PLx ” or the “ Company ”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ [...]
GenMark Diagnostics to Participate in Upcoming Investor Conferences
20/02/2019
CARLSBAD, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to [...]
Adamas to Present at Two Upcoming Investor Conferences
20/02/2019
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, [...]
Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
20/02/2019
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on Monday, March 4, 2019 [...]
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019
20/02/2019
BURLINGTON, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. [...]
Hoth Therapeutics Inc. Announces Closing of Initial Public Offering
20/02/2019
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications [...]
Profound Medical to Participate in the 2019 BTIG MedTech, Life Science & Diagnostic Tools Conference
20/02/2019
TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR [...]
Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
20/02/2019
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that commencing at 8:00 a.m. Eastern Time (ET) on [...]
T2 Biosystems Announces 2018 Fourth Quarter and Full Year Financial and Operational Results Release and Conference Call Date
20/02/2019
LEXINGTON, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, [...]
Intercept to Announce Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
20/02/2019
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Inovalon Reports Fourth Quarter and Full Year 2018 Results
20/02/2019
Full Year 2018 Highlights Full year revenue of $527.7 million, up 17% year-over-year Full year net loss of $39.2 million, resulting in net loss of $0.27 per share Full year Non-GAAP net income of $39.3 million, [...]
Cutera Appoints Katherine Zanotti and Joseph Whitters to its Board of Directors
20/02/2019
BRISBANE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CUTERA, INC., (Nasdaq: CUTR ) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, [...]
Cutera Reports Fourth Quarter and Full Year 2018 Financial Results
20/02/2019
Total truSculpt® Body Sculpting Generated 32% Revenue Growth in 2018 BRISBANE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), a leading provider of laser and other [...]
Achaogen Announces Closing of $15 Million Underwritten Public Offering
20/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug [...]
HTG Molecular Announces an Amendment and Extension to its Precision Diagnostic Partnership (PDP) Two
20/02/2019
TUCSON, Ariz., Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its second [...]

Pages